ReviewInflammopharmacology2026
Bacopa monnieri and Alzheimer's disease: mechanistic convergence, cognitive outcomes and translational perspectives.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), the leading cause of age-related cognitive decline and dementia, represents a growing neurological and socioeconomic burden, while currently approved therapies offer limited symptomatic benefit and minimal disease modification. Bacopa monnieri (L.) Wettst. (BM), a traditional Ayurvedic nootropic herb, has emerged as a promising phytotherapeutic candidate owing to its bioactive bacosides, which target multiple molecular pathways implicated in AD pathogenesis. This review, conducted following PRISMA 2020 principles, critically synthesizes evidence on the therapeutic relevance of BM in AD and cognitive decline. Literature from PubMed, Scopus, Web of Science and Cochrane Library was evaluated to examine phytochemistry, pharmacological mechanisms, preclinical and clinical evidence, cognitive outcomes, pharmacokinetics, safety, formulation strategies, comparative medicinal plant mechanisms and pharmacoeconomic positioning. Mechanistically, bacosides exert neuroprotective effects through cholinergic modulation, attenuation of amyloid-β accumulation, suppression of tau hyperphosphorylation via GSK-3β regulation, enhancement of brain-derived neurotrophic factor (BDNF)-mediated neuroplasticity and mitigation of oxidative stress and neuroinflammation through NF-κB signaling modulation. Preclinical findings consistently demonstrate improvements in cognition, synaptic plasticity and neuronal survival, whereas clinical studies using standardized extracts report favorable effects on memory, attention and processing speed with acceptable tolerability. Comparative analysis positions BM among promising neuroprotective medicinal plants for cognitive enhancement and supports its relevance to SDGs 3, 12 and 15. Nevertheless, variability in extract standardization, limited long-term clinical evidence and absent Alzheimer-specific pharmacoeconomic evaluations warrant biomarker-driven, large-scale randomized trials to clarify its therapeutic utility in AD.
Indexed as
Identifiers
42616216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.